125 related articles for article (PubMed ID: 7521441)
1. [Anti-interferon antibody in chronic hepatitis C].
Arai K; Shindo M; Okuno T
Nihon Rinsho; 1994 Jul; 52(7):1929-34. PubMed ID: 7521441
[TBL] [Abstract][Full Text] [Related]
2. The interferon-alpha 2b gene in Japanese patients with chronic viral hepatitis who developed antibodies after treatment with recombinant interferon-alpha 2a.
Hosoi H; Imai M; Yamanaka M
J Gastroenterol Hepatol; 1992; 7(4):411-6. PubMed ID: 1515568
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases.
Bayraktar Y; Bayraktar M; Gurakar A; Hassanein TI; Van Thiel DH
Hepatogastroenterology; 1997; 44(14):417-25. PubMed ID: 9164512
[TBL] [Abstract][Full Text] [Related]
4. Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors.
Oberg K; Alm GV
J Interferon Res; 1989 Sep; 9 Suppl 1():S45-9. PubMed ID: 2809277
[TBL] [Abstract][Full Text] [Related]
5. Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations.
Antonelli G; Currenti M; Turriziani O; Dianzani F
J Infect Dis; 1991 Apr; 163(4):882-5. PubMed ID: 1901335
[TBL] [Abstract][Full Text] [Related]
6. Anti-interferon antibodies to interferon-alpha 2b: results of comparative assays and clinical perspective.
Spiegel RJ; Jacobs SL; Treuhaft MW
J Interferon Res; 1989 Sep; 9 Suppl 1():S17-24. PubMed ID: 2553829
[TBL] [Abstract][Full Text] [Related]
7. [The influence of anti-interferon-alpha 2a antibodies in initial daily four-week interferon-alpha 2a therapy for chronic hepatitis C].
Habu D; Mizuno M; Ohnishi K; Watanabe A; Son J; Iwano M; Murakoshi R; Takino T; Mizuma Y; Kobayashi M
Nihon Shokakibyo Gakkai Zasshi; 1997 May; 94(5):319-27. PubMed ID: 9170879
[TBL] [Abstract][Full Text] [Related]
8. Interferon-alpha neutralizing antibodies in HIV and chronic HCV patients treated with natural-source human leukocyte-derived interferon-alpha n3.
Zhao XX; Hua J; Smith T; Ferencz-Biro K; Liao MJ; Rashidbaigi A
Hum Antibodies; 1997; 8(3):129-36. PubMed ID: 9322083
[TBL] [Abstract][Full Text] [Related]
9. Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN.
Milella M; Antonelli G; Santantonio T; Giannelli G; Currenti M; Monno L; Turriziani O; Pastore G; Dianzani F
Hepatogastroenterology; 1995 Jul; 42(3):201-4. PubMed ID: 7590565
[TBL] [Abstract][Full Text] [Related]
10. Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2 alpha.
Bonetti P; Diodati G; Drago C; Casarin C; Scaccabarozzi S; Realdi G; Ruol A; Alberti A
J Hepatol; 1994 Mar; 20(3):416-20. PubMed ID: 7516951
[TBL] [Abstract][Full Text] [Related]
11. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection.
Milella M; Antonelli G; Santantonio T; Currenti M; Monno L; Mariano N; Angarano G; Dianzani F; Pastore G
Liver; 1993 Jun; 13(3):146-50. PubMed ID: 8336526
[TBL] [Abstract][Full Text] [Related]
12. Low incidence of neutralizing antibody formation to interferon-alpha 2b in human recipients.
Dianzani F; Antonelli G; Amicucci P; Cefaro A; Pintus C
J Interferon Res; 1989 Sep; 9 Suppl 1():S33-6. PubMed ID: 2681442
[TBL] [Abstract][Full Text] [Related]
13. Humoral response to recombinant interferon-alpha 2b in patients receiving recombinant interferon-alpha 2b therapy.
von Wussow P; Jakschies D; Freund M; Deicher H
J Interferon Res; 1989 Sep; 9 Suppl 1():S25-31. PubMed ID: 2809276
[TBL] [Abstract][Full Text] [Related]
14. Does the presence of serum autoantibodies influence the responsiveness to interferon-alpha 2a treatment in chronic hepatitis C?
Wada M; Kang KB; Kinugasa A; Shintani S; Sawada K; Nishigami T; Shimoyama T
Intern Med; 1997 Apr; 36(4):248-54. PubMed ID: 9187562
[TBL] [Abstract][Full Text] [Related]
15. Detection of anti-interferon-alpha 2a antibodies in chronic liver disease.
Ikeda Y; Miyake K; Toda G; Yamada H; Yamanaka M; Oka H
J Gastroenterol Hepatol; 1989; 4(5):411-8. PubMed ID: 2491207
[TBL] [Abstract][Full Text] [Related]
16. Antibodies to interferon-alpha 2 in patients treated with interferon-alpha 2 for hairy cell leukemia.
Bekisz JB; zur Nedden DL; Enterline JC; Zoon KC
J Interferon Res; 1989 Sep; 9 Suppl 1():S1-7. PubMed ID: 2809275
[TBL] [Abstract][Full Text] [Related]
17. Neutralizing anti-interferon-alpha antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (alpha 2a) and lymphoblastoid interferon-alpha.
Russo D; Candoni A; Zuffa E; Minisini R; Silvestri F; Fanin R; Zaja F; Martinelli G; Tura S; Botta G; Baccarani M
Br J Haematol; 1996 Aug; 94(2):300-5. PubMed ID: 8759890
[TBL] [Abstract][Full Text] [Related]
18. Antibodies developing against a single recombinant interferon protein may neutralize many other interferon-alpha subtypes.
Brand CM; Leadbeater L; Bellati G; Marotta F; Ideo G
J Interferon Res; 1993 Apr; 13(2):121-5. PubMed ID: 7685368
[TBL] [Abstract][Full Text] [Related]
19. [Clinical significance of antibody to Y19 protein in nonA and nonB chronic liver disease].
Sakashita H
Fukuoka Igaku Zasshi; 1993 Apr; 84(4):159-72. PubMed ID: 7686128
[TBL] [Abstract][Full Text] [Related]
20. Loss of interferon antibodies during prolonged continuous interferon-alpha 2a therapy in hairy cell leukemia.
Steis RG; Smith JW; Urba WJ; Venzon DJ; Longo DL; Barney R; Evans LM; Itri LM; Ewel CH
Blood; 1991 Feb; 77(4):792-8. PubMed ID: 1704264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
